EUCTR2010-022207-22-GR进行中(未招募)不适用
A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to one or more TNF-a Inhibitors
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 入组人数
- 555
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients will be male and female aged =18 years of age with a diagnosis of moderately to severely active adult onset RA
- •Diagnosis of Rheumatoid Arthritis (RA) of more than 6 months and less than 15 years
- •At least 8 tender and swollen joints
- •An abnormally high C-reactive protein (CRP) level or erythrocyte sedimentation rate (ESR)
- •Positive for Rheumatoid Factor (RF) or Anti-cyclic citrullinated peptide (CCP) antibody
- •Previously treated with biologic TNF-a inhibitor therapy (infliximab, certolizumab, golimumab, etanercept, adalimumab) and stopped treatment due to insufficient efficacy or intolerance
- •Regular use of at least one conventional disease-modifying anti-rheumatic drug (DMARD), with a stable dose for at least 8 weeks prior to study start
- •Woman must not be pregnant, breastfeeding, or become pregnant during the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Use of unstable doses of non-steroidal inflammatory drugs (NSAIDS) in the past 6 weeks
- •Steroid injection or intravenous (IV) infusion in the last 6 weeks
- •Use of more than 10 mg/day of oral steroids in the last 6 weeks
- •History of a serious reaction to other biological DMARDs
- •Use of an oral calcineurin inhibitor (e.g., cyclosporin or tacrolimus) in the last 8 weeks
- •Surgery on a joint or other major surgery less than 2 months ago, or plans to have joint surgery or major surgery during the study
- •Active fibromyalgia, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease, ulcerative colitis, psoriatic arthritis, or other systemic inflammatory condition except RA
- •Cervical cancer or squamous skin cancer within the past 3 years, or other cancer within the past 5 years
- •Received a live vaccine received within the past 12 weeks (for example, vaccines for measles, mumps, rubella, and chicken pox, and nasal-spray flu vaccines)
- •Hepatitis or human immunodeficiency virus (HIV)
- •A serious bacterial infection (for example, pneumonia or cellulitis) within 3 months or a serious bone or joint infection within 6 months
- •Symptoms of herpes zoster or herpes simplex within the last month
- •Active or latent tuberculosis (TB)
- •Current symptoms of a serious disorder or illness
- •Use of an investigational drug within the last month
研究者
相似试验
进行中(未招募)
1 期
A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTD.Frontotemporal Dementia.MedDRA version: 21.1Level: PTClassification code 10068968Term: Frontotemporal dementiaSystem Organ Class: 10029205 - Nervous system disordersEUCTR2019-004066-18-ITAlector Inc.180
进行中(未招募)
1 期
A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTD followed by An Open-Label Study to Evaluate Long-Term Safety and Tolerability of AL001 in FTD.MedDRA version: 21.1Level: PTClassification code 10068968Term: Frontotemporal dementiaSystem Organ Class: 10029205 - Nervous system disordersFrontotemporal DementiaEUCTR2019-004066-18-DEAlector Inc.110
进行中(未招募)
不适用
A Study in Patients With Rheumatoid Arthritis(FLEX-V)MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2010-022207-22-PLEli Lilly and Company555
进行中(未招募)
1 期
A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTDMedDRA version: 21.1Level: PTClassification code 10068968Term: Frontotemporal dementiaSystem Organ Class: 10029205 - Nervous system disordersFrontotemporal DementiaEUCTR2019-004066-18-NLAlector Inc.180
进行中(未招募)
1 期
A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTDFrontotemporal DementiaEUCTR2019-004066-18-FRAlector Inc.180
